Published in Drug Week, August 7th, 2009
Exelon took this action in light of the proxy vote results announced at the NRG annual meeting.
"The NRG shareholders have spoken, and Exelon will move on. We wish NRG and its owners well," said John Rowe, chairman and chief executive officer of Exelon.
The Company said it believed it could have been successful in completing the transaction, but it was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.